Revlimid might be the flagship, but growth will come from the newer drugs.
Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.
Cisco Systems spent $7.5 billion on share buybacks in the last 4 quarters alone. Here's why that's actually a good idea.
When it comes to getting the job done, these three CEOs are supreme.
Apple Pay has a lot going for it already, but there's another reason why Apple's new payments service looks so promising.
The smooth stylings of jazz saxophonist Kenny G work for the stock market, too.
Regardless of what you think about politics, Warren Buffett has made a number of smart predictions in the past.
AbbVie's board recommends that the company not purchase Shire.
One quarter closer to separation, eBay Marketplaces continues to struggle as PayPal outperforms.
Amgen's drug development pipeline is expected to deliver data on 10 late-stage candidates between 2014 and 2016. Find out what three studies are Amgen's most critical, as well as whether or not Amgen stock has the potential to head higher.